The Netherlands
Synaffix, a Lonza Company, is a pioneering biotech firm founded in 2014 and headquartered in The Netherlands. It boasts a proprietary, clinical-stage technology platform focused on antibody-drug conjugates (ADCs), renowned for optimizing safety and efficacy.
The platform's value is underscored by more than $7.6 billion in technology out-licensing deals with major partners such as ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, and Kyowa Kirin. These collaborations have resulted in the development of over 20 ADCs, with five already in Phase 1 clinical trials.
Synaffix's innovative platform is also addressing unmet medical needs in promising sectors like immune cell engagers and targeted gene therapy. Protected by patents until at least 2039, their technology offers an attractive proposition for investors. The firm's acquisition by Lonza in May 2023, following a €100 million investment from Onza Capital, further validates its potential in the biotechnology arena.
